Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 173

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 173
---
 additional capital in order to preserve, maintain or grow the joint venture and its investments;

●Our joint venture collaborators may have economic or other business interests or goals that are inconsistent with our business interests
or goals and that could affect our ability to fully benefit from the assets owned by the joint venture;

●Our joint venture collaborators may be subject to different laws or regulations than us, which could create conflicts of interest;

●Disagreements with our joint venture investors could result in litigation or arbitration that could be expensive and distracting to
management and could delay important decisions.

Any of the foregoing risks could have a material adverse effect on
our business, financial condition and results of operations.

69

Risks Related to Intellectual Property

Our success depends on our ability to protect our intellectual
property and our proprietary technology, and we may not be able to protect our intellectual property rights throughout the world.

Our success is to a certain degree also dependent
on our ability to obtain and maintain protection of our intellectual property portfolio where applicable, to receive/maintain orphan drug
designation/status and resulting marketing exclusivity for our drug candidates, and we may not be able to protect our intellectual property
rights throughout the world.

We may be materially adversely affected by our
failure or inability to protect our intellectual property rights. Without the granting of these rights, the ability to pursue damages
for infringement would be limited. Similarly, any know-how that is proprietary or particular to our technologies may be subject to risk
of disclosure by employees or consultants despite having confidentiality agreements in place.

Any future success will depend in part on whether
we can obtain and maintain patents to protect our own products and technologies; obtain licenses to the patented technologies of third
parties; and operate without infringing on the proprietary rights of third parties. As noted above, we are currently exploring potential
patent protection strategies for our lead drug candidate, PSX-001. However, these efforts may be unsuccessful. Biotechnology patent matters
can involve complex legal and scientific questions, and it is impossible to predict the outcome of biotechnology and pharmaceutical patent
claims. Any of our future patent applications may not be approved, or we may not develop additional products or processes that are patentable.
Filing, prosecuting and defending patents on drug candidates in all countries throughout the world would be prohibitively expensive. In
addition, the laws of some international countries do not protect intellectual property rights to the same extent as federal or state
laws in the United States. For instance, some countries in which we may sell our